Passive immunoprophylaxis with specific monoclonal antibody confers partial protection against Pneumocystis carinii pneumonitis in animal models.
about
Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugsThe carboxyl terminus of Pneumocystis carinii glycoprotein A encodes a functional glycosylphosphatidylinositol signal sequence.Characterization of major surface glycoprotein genes of human Pneumocystis carinii and high-level expression of a conserved region.Expression, structure, and location of epitopes of the major surface glycoprotein of Pneumocystis carinii f. sp. carinii.Immunological features of Pneumocystis carinii infection in humans.Single and combined humoral and cell-mediated immunotherapy of Pneumocystis carinii pneumonia in immunodeficient scid mice.Proliferative and cytokine responses to a major surface glycoprotein of Pneumocystis carinii.Activated pulmonary macrophages are insufficient for resistance against Pneumocystis carinii.Immunization with Pneumocystis carinii gpA is immunogenic but not protective in a mouse model of P. carinii pneumonia.Antibody to Pneumocystis carinii protects rats and mice from developing pneumonia.MyD88 signaling regulates both host defense and immunopathogenesis during pneumocystis infectionPassive intranasal monoclonal antibody prophylaxis against murine Pneumocystis carinii pneumonia.Purification and characterization of a major human Pneumocystis carinii surface antigenPrevention of infection caused by Pneumocystis carinii in transplant recipients.Combination exposure to zidovudine plus sulfamethoxazole-trimethoprim diminishes B-lymphocyte immune responses to Pneumocystis murina infection in healthy miceSerologic responses to recombinant Pneumocystis jirovecii major surface glycoprotein among Ugandan patients with respiratory symptoms.Molecular characterization of clustered variants of genes encoding major surface antigens of human Pneumocystis cariniiHumoral immune responses to Pneumocystis jirovecii antigens in HIV-infected and uninfected young children with pneumocystis pneumoniaGlycoproteins composed of major surface immunodeterminants of Pneumocystis carinii.Properties of the major antigens of rat and human Pneumocystis cariniiActive immunity to Pneumocystis carinii reinfection in T-cell-depleted mice.Antibody immunity and invasive fungal infectionsAntibody-mediated shift in the profile of glycoprotein A phenotypes observed in a mouse model of Pneumocystis carinii pneumoniaBoth immunity and hyperresponsiveness to Pneumocystis carinii result from transfer of CD4+ but not CD8+ T cells into severe combined immunodeficiency miceConserved sequence homology of cysteine-rich regions in genes encoding glycoprotein A in Pneumocystis carinii derived from different host species.Antibody response to Pneumocystis jirovecii major surface glycoprotein.Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients.Colonization by Pneumocystis jirovecii and its role in disease.The biology of Pneumocystis carinii.Development and resolution of Pneumocystis carinii pneumonia in severe combined immunodeficient mice: a morphological study of host inflammatory responses.Immunity against the opportunistic fungal pathogen Pneumocystis.The ecology of pneumocystis: perspectives, personal recollections, and future research opportunitiesVaccine-Induced Immunogenicity and Protection Against Pneumocystis Pneumonia in a Nonhuman Primate Model of HIV and Pneumocystis Coinfection.Current understanding of Pneumocystis immunology.Specific T-cell response to a Pneumocystis carinii surface glycoprotein (gp120) after immunization and natural infectionPneumocystis colonization in immunocompetent and simian immunodeficiency virus-infected cynomolgus macaquesEffect of bronchoalveolar lavage fluid from Pneumocystis carinii-infected hosts on phagocytic activity of alveolar macrophages.Long-term serologic responses to the Pneumocystis jirovecii major surface glycoprotein in HIV-positive individuals with and without P. jirovecii infection.Geographical variation in serological responses to recombinant Pneumocystis jirovecii major surface glycoprotein antigens.Passive immunization of neonatal mice against Pneumocystis carinii f. sp. muris enhances control of infection without stimulating inflammation.
P2860
Q28316964-EA413D34-1D52-42FD-B7A8-94E4888A3094Q32016644-2B83BE1F-9C9F-4534-8DCF-3ED98239337EQ32035981-6A28051F-91F5-4C42-A43A-926C114D0C66Q32129778-FE78E043-DC0C-499F-A92C-D5621F7CF6FCQ33538931-1933C054-EC35-4DE1-869C-C112A0CC836CQ33594578-25BB4BC6-F215-4A3F-B9E7-B78C493FC66DQ33614029-C38CD764-F369-4F77-B1E0-E291C63F6A17Q33748787-2F12E879-76E1-48AD-9808-BFA99731634DQ33756204-F742F2BA-FED0-42F6-B7B4-CABAD139ED6BQ33993403-2A33CC41-7A1A-48F9-86B3-9B04C7ABA440Q34074728-780E34FA-B3D0-4E22-B125-552072265D99Q34119407-381F84DC-96DD-4AEB-B0C3-6D2415D521A3Q34176324-7EC8E9D5-911E-4F63-B04A-41A24D963DE6Q34374874-35D0EBA3-88C7-49B2-8CE2-8169BAC00004Q34429315-98DAD3CE-1327-4165-9DFB-A2D1FE99CB96Q34531964-6A94F10A-283D-44BA-B245-B6DD7DF99357Q34532020-9236DAB1-A6CC-45B9-969B-053F20C8E9A0Q35080065-A1AC8442-398D-4FD2-8734-AAAD2BF5AED2Q35095181-D907146E-ED4F-4A7C-BBC3-F9E1A229C4F7Q35096026-BF3B1627-1449-4FD7-9C12-F67826CB0E11Q35420434-445B6EBF-52BB-4396-8784-B55EFA48F6F1Q35447692-0865CBB7-766F-4285-B9FF-E2445BFBA2C2Q35493977-4EF68114-6A2E-49A8-BFBE-985C7DE23159Q35605922-85A8CA87-62E1-46B8-895E-A9535EC7BD8CQ35777995-0BDA09F4-05D3-4D26-B820-6225FE737E07Q35793264-8ECB3E60-4F63-4744-946D-DE410E5471F9Q35920640-B37A398B-A512-4188-808A-C7DB5B10AEBAQ35940586-DE7DD5BB-7499-4B4A-BDF2-5BB4910958D8Q35949839-FDC5B91A-F4F7-4695-8109-28E2D0E4D3E9Q36029615-BF76583E-4368-4597-9CD5-9FBF4649202BQ36042827-5735F868-8AA1-4757-B36F-4A02F6AE1B1EQ36082802-C583DCEC-FBB4-41CE-A7BF-70D76A2A998BQ36816620-771B2EF1-97AF-4C27-8498-E1B64DF43823Q36984703-12CBEA9F-0CD9-4C7E-8D58-A10870A987F1Q36987498-B8AE76ED-A3F2-4787-9E79-164F266E1C1DQ37054985-F56DDF07-4BEA-4FAB-897E-30375FF349FDQ37116982-3DE9AB89-08B0-4347-8415-955FE6F05AECQ37272778-F2094345-6CFC-4C0F-85D6-5B719337A9FBQ37396829-951A5098-D4B1-48A7-9A4A-6094E6BDE367Q37582861-445B7687-83CF-47E8-B4A2-DEA98BA48D29
P2860
Passive immunoprophylaxis with specific monoclonal antibody confers partial protection against Pneumocystis carinii pneumonitis in animal models.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
1988年论文
@zh
1988年论文
@zh-cn
name
Passive immunoprophylaxis with ...... pneumonitis in animal models.
@ast
Passive immunoprophylaxis with ...... pneumonitis in animal models.
@en
type
label
Passive immunoprophylaxis with ...... pneumonitis in animal models.
@ast
Passive immunoprophylaxis with ...... pneumonitis in animal models.
@en
prefLabel
Passive immunoprophylaxis with ...... pneumonitis in animal models.
@ast
Passive immunoprophylaxis with ...... pneumonitis in animal models.
@en
P2860
P356
P1476
Passive immunoprophylaxis with ...... pneumonitis in animal models.
@en
P2093
F Gigliotti
W T Hughes
P2860
P304
P356
10.1172/JCI113503
P407
P577
1988-06-01T00:00:00Z